Protein detail
NK1R
Substance-P receptor (SPR) (NK-1 receptor) (NK-1R) (Tachykinin receptor 1)
Entry name NK1R | UniProt ID | EVMP confidence score 0.50 |
Supporting publications (n) 1 | Transmembrane count 7 | Protein classification FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins |
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40Basic Information13
Protein Names
Substance-P receptor (SPR) (NK-1 receptor) (NK-1R) (Tachykinin receptor 1)
Protein Class (3)
FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins
Protein Function (2)
- FDA approved drug targets:Small molecule drugs
- G-protein coupled receptors:GPCRs excl olfactory receptors
Transmembrane
32..54; Helical; Name=1; 65..86; Helical; Name=2; 107..128; Helical; Name=3; 149..169; Helical; Name=4; 195..219; Helical; Name=5; 249..270; Helical; Name=6; 284..308; Helical; Name=7
Transmembrane Count
7
Ensembl
Entrez Gene Symbol
Gene Synonym (4)
NK1RNKIRSPRTAC1R
Gene Description
Tachykinin receptor 1
Chromosome
2
Position
75046463-75199520
Supporting publications (n)
1
EVMP confidence score
0.50
Fluorescence & Localization3
Tissue SpecificbrainCell SpecificAstrocytesSingle-Nuclei Brain Specificastrocyte
Function & Pathway8
Protein Function (2)
- FDA approved drug targets:Small molecule drugs
- G-protein coupled receptors:GPCRs excl olfactory receptors
Cellular Component (8)
Molecular Function (3)
Biological Process (3)
KEGG (3)
Reactome (10)
- R-hsa-8856825 cargo recognition for clathrin mediated endocytosis
- R-hsa-373076 class a 1 rhodopsin like receptors
- R-hsa-8856828 clathrin mediated endocytosis
- R-hsa-500792 gpcr ligand binding
- R-hsa-416476 g alpha q signalling events
- R-hsa-199991 membrane trafficking
- R-hsa-375276 peptide ligand binding receptors
- R-hsa-372790 signaling by gpcr
- R-hsa-380095 tachykinin receptors bind tachykinins
- R-hsa-5653656 vesicle mediated transport
Canonical Pathways
M169 Pid integrin2 pathway
Mediation Categories (4)
Clinical-translation mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation
Relations & Evidence60
Ligand-Receptor Signaling (46)
46 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| gpcr | receptor | Almen2009 | No | Yes | No | No | No |
| rhodopsin | receptor | Almen2009 | No | Yes | No | No | No |
| gpcr | receptor | UniProt_keyword | No | Yes | No | No | No |
| rhodopsin | receptor | Surfaceome | No | Yes | No | No | No |
| gpcr | receptor | Surfaceome | No | Yes | No | No | No |
| class_a_rhodopsin | receptor | GPCRdb | No | Yes | No | No | No |
| class_a_rhodopsin_peptide | receptor | GPCRdb | No | Yes | No | No | No |
| class_a_rhodopsin_peptide_tachykinin | receptor | GPCRdb | No | Yes | No | No | No |
| receptor | receptor | OmniPath | No | Yes | No | No | No |
| transmembrane | transmembrane | UniProt_location | No | No | No | No | No |
Regulatory Interaction Network (11)
11 records.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| NK1R | P25103 | GNA14 | O95837 | Yes | Yes | No | WangSIGNOR | SIGNOR:31160049 |
| NK1R | P25103 | GNAI3 | P08754 | Yes | Yes | No | SIGNOR | SIGNOR:31160049 |
| NK1R | P25103 | GNAZ | P19086 | Yes | Yes | No | SIGNOR | SIGNOR:31160049 |
| NK1R | P25103 | GNAQ | P50148 | Yes | Yes | No | WangSIGNOR | SIGNOR:31160049 |
| NK1R | P25103 | GNAO | P09471 | Yes | Yes | No | SIGNOR | SIGNOR:31160049 |
| NK1R | P25103 | GNAL | P38405 | Yes | Yes | No | SIGNOR | SIGNOR:31160049 |
| NK1R | P25103 | GNAS3 | O95467 | Yes | Yes | No | HINTSIGNOR | HINT:37973972HINT:34711980SIGNOR:31160049 |
| NK1R | P25103 | ALEX | P84996 | Yes | Yes | No | HINTSIGNOR | HINT:37973972HINT:34711980SIGNOR:31160049 |
| NK1R | P25103 | GNAS2 | P63092 | Yes | Yes | No | HINTSIGNOR | HINT:37973972HINT:34711980SIGNOR:31160049 |
| NK1R | P25103 | GNAS1 | Q5JWF2 | Yes | Yes | No | HINTSIGNOR | HINT:37973972HINT:34711980SIGNOR:31160049 |
Page 1 of 2Next
Protein Complex Composition (2)
Isolation & Detection Technology (1)
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Differential UltracentrifugationSize Exclusion Chromatography | Mass spectrometry | 1 | 40748658 |
Sequence, Structure & Domains13
Sequences
Length
407
Mass
46,251
Sequence
MDNVLPVDSDLSPNISTNTSEPNQFVQPAWQIVLWAAAYTVIVVTSVVGNVVVMWIILAHKRMRTVTNYFLVNLAFAEASMAAFNTVVNFTYAVHNEWYYGLFYCKFHNFFPIAAVFASIYSMTAVAFDRYMAIIHPLQPRLSATATKVVICVIWVLALLLAFPQGYYSTTETMPSRVVCMIEWPEHPNKIYEKVYHICVTVLIYFLPLLVIGYAYTVVGITLWASEIPGDSSDRYHEQVSAKRKVVKMMIVVVCTFAICWLPFHIFFLLPYINPDLYLKKFIQQVYLAIMWLAMSSTMYNPIIYCCLNDRFRLGFKHAFRCCPFISAGDYEGLEMKSTRYLQTQGSVYKVSRLETTISTVVGAHEEEPEDGPKATPSSLDLTSNCSSRSDSKTMTESFSFSSNVLS
Alternative Products
Event=Alternative splicing; Named isoforms=2; Name=1; IsoId=P25103-1; Sequence=Displayed; Name=2; IsoId=P25103-3; Sequence=VSP_053824
Alternative Sequence
312..407; Missing (in isoform 2)
3D Structural Models
Turn
18..20; 24..26; 320..322; 355..358
Helix
29..58; 61..63; 66..94; 102..135; 144..168; 191..204; 206..225; 238..273; 275..279; 283..308; 310..319
Beta Strand
4..8; 136..139; 169..182; 229..234; 323..325; 335..340; 342..344; 359..361
3D Structure
Electron microscopy (6); NMR spectroscopy (3); X-ray crystallography (4)
Domain & Motif Annotations
Compositional Bias
376..407; Polar residues
Region
364..407; Disordered
Protein Families
G-protein coupled receptor 1 family
Sequence Similarities
Belongs to the G-protein coupled receptor 1 family.
Clinical Relevance6
Disease Involvement
FDA approved drug targets
Related Diseases (28)
Abnormal micturitionAcute diabete complicationAcute upper respiratory infectionAnxiety disorderAsthmaAtopic eczemaChronic obstructive pulmonary diseaseChronic painCoughDepressionEczemaFunctional bladder disorderHypertensionInfluenzaIntracranial injuryIrritable bowel syndromeMenopausal disorderMigraineMood disorderNausea/vomitingOesophagus motility disorderPainPrurigoPsoriasisSchizophreniaSkin tag/polypSolid tumour/cancerSubstance abuse
Biomarker
Phase 2; Phase 1; Terminated; Discontinued in Phase 2; Phase 3; Investigative; Approved; Discontinued in Phase 1; Patented
Drug Targets
FDA approved drug targets
Drugs (37)
APREPITANTVOFOPITANTNULLSERLOPITANTCHEMBL:CHEMBL2203705BURAPITANTCHEMBL:CHEMBL2203708CHEMBL:CHEMBL2203707CHEMBL:CHEMBL2203704CP-122721DAPITANTELINZANETANTFIGOPITANTVESTIPITANTTRADIPITANTAV608LANEPITANTEZLOPITANTCASOPITANTGW 597599NETUPITANTDNK333CHEMBL:CHEMBL1256740ORVEPITANTSELEGILINEFR139317VESTIPITANT MESYLATEFOSNETUPITANT CHLORIDE HYDROCHLORIDEARGIPRESSINCHEMBL:CHEMBL2203703ROLAPITANT HYDROCHLORIDEVAPREOTIDEFOSAPREPITANTRECOMBINANT CYTOKINECHEMBL:CHEMBL2203706CHEMBL:CHEMBL2203709ROLAPITANT
Supporting Publications1
| PMID | Title | Abstract |
|---|---|---|
| 31805958 | Proteomic analysis of cerebrospinal fluid extracellular vesicles reveals synaptic injury, inflammation, and stress response markers in HIV patients with cognitive impairment. | No abstract available |